Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Development of pulmonary tuberculosis following treatment with anti-PD-1 for non-small cell lung cancer.

× No keyword cloud information.

16 in total

1. Active and latent tuberculosis infections in patients treated with immune checkpoint inhibitors in a non-endemic tuberculosis area.

Authors: Gregory R Stroh; Tobias Peikert; Patricio Escalante
Journal: Cancer Immunol Immunother Date: 2021-03-26 Impact factor: 6.968

2. Senescent cells re-engineered to express soluble programmed death receptor-1 for inhibiting programmed death receptor-1/programmed death ligand-1 as a vaccination approach against breast cancer.

Authors: Zehong Chen; Kang Hu; Lieting Feng; Ruxiong Su; Nan Lai; Zike Yang; Shijun Kang
Journal: Cancer Sci Date: 2018-05-22 Impact factor: 6.716

3. PD-1 Expression on Mycobacterium tuberculosis-Specific CD4 T Cells Is Associated With Bacterial Load in Human Tuberculosis.

Authors: Cheryl L Day; Deborah A Abrahams; Rubina Bunjun; Lynnett Stone; Marwou de Kock; Gerhard Walzl; Robert J Wilkinson; Wendy A Burgers; Willem A Hanekom
Journal: Front Immunol Date: 2018-08-31 Impact factor: 7.561

4. Tuberculosis Infection in a Patient Treated With Nivolumab for Non-small Cell Lung Cancer: Case Report and Literature Review.

Authors: Ronwyn van Eeden; Bernardo L Rapoport; Teresa Smit; Ronald Anderson
Journal: Front Oncol Date: 2019-07-24 Impact factor: 6.244

Review 5. Reactivation of tuberculosis in cancer patients following administration of immune checkpoint inhibitors: current evidence and clinical practice recommendations.

Authors: Amalia Anastasopoulou; Dimitrios C Ziogas; Michael Samarkos; John M Kirkwood; Helen Gogas
Journal: J Immunother Cancer Date: 2019-09-04 Impact factor: 13.751

6. PD-1 inhibitors for non-small cell lung cancer patients with special issues: Real-world evidence.

Authors: Seonggyu Byeon; Jang Ho Cho; Hyun Ae Jung; Jong-Mu Sun; Se-Hoon Lee; Jin Seok Ahn; Keunchil Park; Myung-Ju Ahn
Journal: Cancer Med Date: 2020-02-06 Impact factor: 4.452

Review 7. The dark side of immunotherapy.

Authors: Nwanneka Okwundu; Douglas Grossman; Siwen Hu-Lieskovan; Kenneth F Grossmann; Umang Swami
Journal: Ann Transl Med Date: 2021-06

Review 8. Immune Checkpoint Inhibitors in Special Populations.

Authors: Qianyun Shan; Hongyang Lu
Journal: Technol Cancer Res Treat Date: 2021 Jan-Dec

Review 9. [Recommendation of Diagnosis and Management for the Infections Related to Immune Checkpoint Inhibitors].

Authors: Minya Lu; Li Zhang; Yue Li; Hanping Wang; Xiaoxiao Guo; Jiaxin Zhou; Lian Duan; Xiaoyan Si; Yingchun Xu; Li Zhang
Journal: Zhongguo Fei Ai Za Zhi Date: 2019-10-20

10. Anti-PD-1 immunotherapy leads to tuberculosis reactivation via dysregulation of TNF-α.

Authors: Liku B Tezera; Magdalena K Bielecka; Paul Ogongo; Naomi F Walker; Matthew Ellis; Diana J Garay-Baquero; Kristian Thomas; Michaela T Reichmann; David A Johnston; Katalin Andrea Wilkinson; Mohamed Ahmed; Sanjay Jogai; Suwan N Jayasinghe; Robert J Wilkinson; Salah Mansour; Gareth J Thomas; Christian H Ottensmeier; Alasdair Leslie; Paul T Elkington
Journal: Elife Date: 2020-02-24 Impact factor: 8.140